Myriad Genetics: George Daneker
Myriad Genetics appointed George Daneker as president and chief clinical officer of oncology, effective March 18. Daneker will be responsible for leading Myriad's commercial and clinical strategy related to its oncology portfolio. Daneker previously served as system VP for oncology and as medical director of the Oncology Clinical Program at SSM Health, a not-for-profit health system. Prior to that, he served as system corporate chief medical officer at City of Hope.
Guardant Health: Samir Kaul
Guardant Health announced that a member of its board, Samir Kaul, has notified the company that he intends to resign his position on the board and as a member of its compensation committee effective Feb. 1. The firm said that Kaul's resignation is not the result of any dispute or disagreement on any matter relating to its operations, policies, or practices.
Roche: Bernard Poussot
Roche announced that current board of directors member Bernard Poussot will not stand for reelection at the firm's annual general meeting. Poussot has been a board member since 2015 and was previously chairman, president, and CEO of pharmaceutical firm Wyeth. He is also a board member for global food and nutrition company Cargill.
Nebula Genomics: Jason Karkus
Jason Karkus has been appointed as president of Nebula Genomics, a wholly owned subsidiary of ProPhase Labs. Previously, he held several positions, most recently as president at ProPhase Diagnostics, where he expanded the company's COVID laboratory testing business during the pandemic.
Devyser Diagnostics: Michael Uhlin
Devyser Diagnostics has appointed Michael Uhlin to its management team, effective Feb. 1. He has been the company's CSO since fall 2023, and with his additional appointment to the management team, he will be responsible for development and innovation in the areas of bioinformatics, clinical affairs, and the firm's CLIA-certified Devyser Genomic Laboratories. Uhlin also holds a professorship at Karolinska Institutet.
Evosep: Rick Carberry
Rick Carberry has been appointed as VP of the Americas at Danish mass spectrometry proteomics firm Evosep. He has extensive commercial and marketing experience in liquid chromatography mass spectrometry and previously held positions at Waters, Sciex, Agilent Technologies, and Thermo Fisher Scientific.
Enhanc3D Genomics: Daniel Turner
Enhanc3D Genomics, a company specializing in 3D genome mapping tools, has appointed Daniel Turner as CSO. Turner joins the company from Oxford Nanopore Technologies, where he held roles including senior VP, VP, and senior director of applications. He has also served as head of sequencing technology development at the Wellcome Trust Sanger Institute after postdoctoral positions at Wellcome Sanger and Weill Cornell Medical College. He holds a biochemistry degree from the University of Oxford and completed an M.Sc. and Ph.D. in genetics at the University of Manchester Institute of Science and Technology.
Enzo Biochem: Kara Cannon, Patricia Eckert
Enzo Biochem's board has appointed Kara Cannon as CEO and Patricia Eckert as CFO. Both had previously held their respective positions on an interim basis. Cannon earlier had been Enzo's chief operating officer and chief commercial officer. Eckert was the company's VP and senior director of finance prior to being named interim CFO.
Molecular Designs: Michael Clark
Molecular Designs, a Birmingham, Alabama-based provider of PCR assays and solutions for the molecular diagnostics industry, has appointed Michael Clark as its new CEO after previously serving as CFO. Clark has held leadership positions at rehabilitation facility company Mentis Neuro Health and behavioral healthcare firm D&S Community Services. He also served in leadership positions at Dun & Bradstreet and Hewlett Packard and as a portfolio adviser and operator for a family investment office. In addition, Clark founded and operated a financing and marketing services company that served early-stage companies.
CancerIQ: Diedre Mavin Senatra
CancerIQ, precision health platform that uses genetic information to help prevent, detect, and treat cancer, has named Diedre Mavin Senatra as senior VP of commercial strategy. Senatra previosuly spent nearly 20 years at Myriad Genetics, most recently as a strategic account manager, according to her LinkedIn profile. She has also previously worked as a laboratory tech at ARUP Laboratories.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.